Make us your home page
Instagram

Today’s top headlines delivered to you daily.

(View our Privacy Policy)

Antibody therapy offers glimmer of hope in treating Alzheimer's

An initial trial of an antibody therapy that targets Alzheimer's disease has shown promising results and could signal a long-awaited breakthrough in treating the devastating brain disorder that affects over 5 million Americans.

The antibody, known as aducanumab, targets a protein called amyloid beta that builds up in the brain and creates plaques associated with the disease. In a paper published Wednesday in the journal Nature, a trial to evaluate the drug's safety and tolerability showed positive results. Of 165 patients, those who received monthly infusions of the drug for a year showed a significant reduction in amyloid beta and slower cognitive decline than those receiving a placebo.

The therapy is now being tested for efficacy in larger trials. If those are successful, aducanumab could be the first new Alzheimer's drug to be approved in over a decade and the first to reverse signs of the disease.

"Overall, this is the best news that we've had in my 25 years doing Alzheimer's clinical research and it brings new hope for patients and families most affected by the disease," said one of the study's authors, Stephen Salloway, director of neurology in the Memory and Aging program and professor of neurology and psychiatry at Brown University.

Researchers divided recipients into four groups, receiving either a placebo, a low dose of aducanumab, a medium dose or a high dose.

"The higher the dose the larger the degree of reduction, and the longer the treatment, the larger the degree of reduction," said another study author, Roger Nitsch, director at the Institute for Regenerative Medicine at the University of Zurich.

In PET brain scans taken of people receiving the highest dose, "after one year you can see no red on the image, meaning the amyloid has almost completely disappeared," Nitsch said. Compared to past studies, he added, "the effect size of this drug is unprecedented."

Higher doses did result in some adverse reactions among carriers of the APOE4 gene associated with Alzheimer's, including slight brain swelling and bleeding seen in MRI brain scans. But for most recipients this side effect was manageable by careful monitoring and adjusting of the drug, the authors said.

An estimated 5.2 million Americans 65 and older have Alzheimer's, and experts predict that number will nearly triple by 2050 in the absence of new treatments. Five FDA-approved drugs can alleviate some symptoms, but in the past 12 years no new drugs have been approved for the disease, which at $236 billion a year is the most expensive disease in the U.S.

In recent years, several promising therapies have failed to show positive results in later trials. But the technology that can identify amyloid plaques in the brains of living patients — which was used in the new study — has been a game-changer for researchers.

"Before, people (in trials) were screened by cognitive tests and they may or may not have had amyloid," potentially skewing study results, said James Hendrix, director of global science initiatives at the Alzheimer's Association.

"This trial has reinvigorated the field and clearly created a lot more excitement about amyloid as a target," he said of the aducanumab study. "There's been a lot of debate over the last 20 years over the role of amyloid (and) how important it is in the disease." Successful Phase 3 trials of the drug would add strong support for the hypothesis that preventing or clearing amyloid buildup can help patients, he said.

And while experts believe the key to stopping Alzheimer's will ultimately require a combination of approaches, "right now we need one good one, a new one.

"If aducanumab and others in the pipeline have the promise of maybe preventing and slowing down the progression, it could let (people) live out their golden years the way they want to."

Antibody therapy offers glimmer of hope in treating Alzheimer's 08/31/16 [Last modified: Wednesday, August 31, 2016 2:23pm]
Photo reprints | Article reprints

Copyright: For copyright information, please check with the distributor of this item, Washington Post.
    

Join the discussion: Click to view comments, add yours

Loading...
  1. 'Empire' star Grace Byers keynotes USF Women in Leadership & Philanthropy luncheon

    Human Interest

    BY AMY SCHERZER

    TAMPA — The first University of South Florida graduate to address the USF's Women in Leadership & Philanthropy supporters, Grace Gealey Byers, class of 2006, centered her speech on her first name, turning it into a verb to share life lessons.

    Grace Byers, University of South Florida Class of 2006, stars on the Fox television show Empire. She delivered the keynote at the USF Women in Leadership and Philanthropy luncheon Friday. Photo by Amy Scherzer
  2. Southeast Seminole Heights holds candlelight vigil for victims' families and each other

    News

    TAMPA — They came together in solidarity in Southeast Seminole Heights, to sustain three families in their grief and to confront fear, at a candlelight vigil held Sunday night in the central Tampa neighborhood.

    A peaceful march that began on east New Orleans Avenue was held during the candlelight vigil for the three victims who were killed in the recent shootings in the Seminole Heights neighborhood in Tampa on Sunday, October 22, 2017.
  3. It's not just Puerto Rico: FEMA bogs down in Florida, Texas too

    HOUSTON — Outside Rachel Roberts' house, a skeleton sits on a chair next to the driveway, a skeleton child on its lap, an empty cup in its hand and a sign at its feet that reads "Waiting on FEMA."

    Ernestino Leon sits among the debris removed from his family’s flood-damaged Bonita Springs home on Oct. 11. He has waited five weeks for FEMA to provide $10,000 to repair the home.
  4. McConnell says he's awaiting Trump guidance on health care

    STERLING, Va. — Senate Majority Leader Mitch McConnell said Sunday he's willing to bring bipartisan health care legislation to the floor if President Donald Trump makes clear he supports it.

    Senate Majority Leader Mitch McConnell says he’s “not certain yet” on what Trump wants.
  5. Tampa's Lance McCullers shows killer instinct in pitching Astros to World Series

    Ml

    HOUSTON — It felt like the beginning on Saturday night at Minute Maid Park, the arrival of a new force on the World Series stage. The Astros are back, for the first time in a dozen years, and they want to stay a while.

    Houston Astros starting pitcher Lance McCullers (43) throwing in the fifth inning of the game between the Houston Astros and the Tampa Bay Rays in Tropicana Field in St. Petersburg, Fla. on Sunday, July 12, 2015.